Expression of lung resistance protein and correlation with other drug resistance proteins and outcome in myelodysplastic syndromes

Leukemia and Lymphoma

Volumn 29, Issue 5-6, 1998, Pages 547-551

  Lepelley, Pascale ^a   Poulain, Stephanie ^a   Grardel, Nathalie ^a   Preudhomme, Claude ^a   Cosson, Alain ^a   Fenaux, Pierre ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Clinical outcome; Drug resistance proteins; LRP; Lung resistance protein; MDS; Myelodysplasia

Indexed keywords

ANTHRACYCLINE; CD34 ANTIGEN; CYTARABINE; CYTOPLASM PROTEIN; GLYCOPROTEIN P; MONOCLONAL ANTIBODY; PROTEIN BCL 2; PROTEIN P53;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; KARYOTYPE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0031838229     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199809050914     Document Type: Article

References (11)

1. List, A. F. (1993). Multidrug resistance: Clinical relevance in acute leukemia. Oncology, 7, 23-32.
2. Lepelley, P., Soenen, V., Preudhomme, C., Laï, J. L., Cosson, A. and Fenaux, P. (1994). Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes. Leukemia, 8, 998-1004.
3. 1 110,00 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res, 53, 1475-1485.
4. Schuurhuis, G. J., Broxterman, H. J., de Lange, J. H. M., Pinodo, H. M., van Heiningen, T. H. M., Kuiper, C. M., Scheffer, G. L., Scheper, R. J., van Kalken, C. K., Baak, J. P. A. and Lankelma, J. (1991). Early multidrug resistance defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein. Br J Cancer, 64, 857-868.
5. List, A. F., Spier, C. S., Grogan, T. M., Johnson, C., Roe, D. J., Greer, J. P., Wolff, S. N., Broxterman, H. J., Scheper, R. J., Scheffer, G. L. and Dalton, W. S. (1996). Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood, 87, 2464-2469.
6. Bennet, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D., Gralnick, H. and Sultan, C. (1982). Proposals for the classification of myelodysplastic syndromes. Br J Haematol, 51, 189-199.
7. Solary, E., Witz, B., Caillot, D., Moreau, P., Desablens, B., Cahn, J. Y., Sadoun, A., Pignon, B., Berthou, C., Maloisel, F., Guyotat, D., Casassus, P., Ifrah, N., Lamy, Y., Audhuy, B., Colombat, P. and Harousseau, J. L. (1996). Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: A randomized multicenter study. Blood, 88, 1198-1205.
8. Lepelley, P., Preudhomme, C., Vanrumbeke, M., Quesnel, B., Cosson, A. and Fenaux, P. (1994). Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis. Leukemia, 8, 1342-1349.
9. Lepelley, P., Soenen, V., Preudhomme, C., Merlat, A., Cosson, A. and Fenaux, P. (1995). Bc12 expression in myelodysplastic syndromes and its correlation with hematological features, p53 mutations and prognosis. Leukemia, 9, 726-730.
10. Campos, L., Rouault, J. P., Sabido, O., Oriol, P., Roubi, N., Vasselon, C., Archimbaud, E., Magaud, J. P. and Guyotat, D. (1993). High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood, 81, 3091-3096.
11. Wattel, E., Preudhomme, C., Hecquet, B., Vanrumbeke, M., Quesnel, B., Dervite, I., Morel, P. and Fenaux, P. (1994). p53 mutations are associated to resistance to chemotherapy and short survival in hematological malignancies. Blood, 84, 3148-3157.